Event Overview

An antibody's increased tendency to bind itself at high concentrations limits its stability. As such, scientists must carefully characterize self-interaction when selecting molecules for pharmaceutical applications. However, researchers often have only scarce sample amounts during early-stage development, which prevents them from using many self-interaction analysis methods. Techniques to assess antibody self-interactions with only micrograms of protein are urgently needed.

In this webinar, brought to you by Sartorius, Martin Domnowski, a former researcher at the Ludwig Maximilian University of Munich, will discuss how Bio-Layer Interferometry (BLI) quickly and reliably identifies antibodies with a strong tendency for self-interaction. Moreover, he will present mitigation strategies for reducing antibody self-interaction, such as specific formulation excipients and rational mutagenesis.

Topics to be covered

  • Antibody self-interaction in pharmaceutical drug development
  • Using Octet® BLI technology for monoclonal antibody formulation development
  • Identifying antibody variants with lower self-interaction tendencies

  • Wednesday, March 16, 2022

    10:00 AM Eastern Time (3:00 PM CET)

    This webinar will also be available on-demand.

    Meet the speakers

    Martin Domnowski, PhD
    Pharmaceutical Technology and Biopharmaceutics
    Ludwig Maximilian University

    David Apiyo, PhD
    Manager of Applications Scientists
    BioAnalytics Applications

    Sponsored by



    TS_Webinar_Bio-Rad_LabTools_Droplet Digital PCR: When qPCR Doesn’t Make the Cut November 4, 2021_IO#403220

    You must have Javascript and Cookies enabled to access this webcast.

    Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.